Skip to main content

Topbar

  • Newsroom
  • Contact
  • Global Site
Home
  • About
  • Our Science
  • ONO Group Pipeline
     

    Our Pipeline

    We’re investigating a range of therapies with the potential to make a meaningful difference in patients’ lives.

    Learn More

  • Contact
  • Global Site
  • Newsroom

Newsroom

Stay up to date with what’s happening at ONO PHARMA USA.

Doctor meeting with a patient

Breadcrumb

  1. Newsroom

ONO PHARMA USA Announces the Initiation of Phase 2 Study of Tirabrutinib, a BTK Inhibitor, in Patients with Primary Central Nervous System Lymphoma
R & D
July 19, 2021
Ono Pharmaceutical Co., Ltd. Announced 2020 Full Year Financial Results
Company
May 11, 2021
Announcement of New Office Establishment
Company
April 27, 2021
Ono Pharmaceutical Co., Ltd. Joins the University of California Drug Discovery Consortium
Company
March 26, 2021
Ono Pharmaceutical Co., Ltd. Entered Sponsorship Agreements with LabCentral and MBC BioLabs
Company
March 17, 2021
Ono Pharmaceutical Co., Ltd. Announces 2020 3Q Financial Results
Company
February 1, 2021
ONO PHARMA USA launches a new website.
Company
December 25, 2020

Pagination

  • First page « First
  • Previous page ‹
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
ONO Pharma Logo
Copyright ©2023 ONO PHARMA USA, INC.
All rights reserved.

Footer

  • Terms of Use
  • Privacy Policy
  • Compliance

About Us

  • About Us
  • Mission & Values

Our Science

  • Our Science

Footer 2

  • ONO Group Pipeline

You’re getting ready to leave the ONO PHARMA USA Website.

Thank you for visiting the ONO PHARMA USA, INC. website. This link will take you to an external website.

Proceed to External Website

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy.